Intellia Therapeutics (NTLA) Short Interest Ratio & Short Volume $8.64 -0.23 (-2.59%) Closing price 04:00 PM EasternExtended Trading$8.70 +0.06 (+0.69%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Intellia Therapeutics Short Interest DataIntellia Therapeutics (NTLA) has a short interest of 28.51 million shares, representing 28.92% of the float (the number of shares available for trading by the public). This marks a 5.83% increase in short interest from the previous month. The short interest ratio (days to cover) is 8.5, indicating that it would take 8.5 days of the average trading volume of 2.41 million shares to cover all short positions.Current Short Interest28,510,000 sharesPrevious Short Interest26,940,000 sharesChange Vs. Previous Month+5.83%Dollar Volume Sold Short$209.83 millionShort Interest Ratio8.5 Days to CoverLast Record DateApril 15, 2025Outstanding Shares103,517,000 sharesShort Percent of Float28.92%Today's Trading Volume2,125,521 sharesAverage Trading Volume2,408,945 sharesToday's Volume Vs. Average88% Short Selling Intellia Therapeutics? Sign up to receive the latest short interest report for Intellia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNTLA Short Interest Over TimeNTLA Days to Cover Over TimeNTLA Percentage of Float Shorted Over Time Intellia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202528,510,000 shares $209.83 million +5.8%28.9%8.5 $7.36 3/31/202526,940,000 shares $191.54 million +0.9%27.3%7.7 $7.11 3/15/202526,690,000 shares $243.95 million +2.5%27.1%8.5 $9.14 2/28/202526,040,000 shares $262.74 million +6.6%26.4%8.5 $10.09 2/15/202524,420,000 shares $261.29 million +1.5%24.8%8.4 $10.70 1/31/202524,060,000 shares $248.30 million No ChangeN/A8.7 $10.32 1/15/202524,060,000 shares $233.62 million +11.0%N/A8.2 $9.71 12/31/202421,670,000 shares $252.67 million +9.4%N/A7.9 $11.66 12/15/202419,810,000 shares $255.55 million +4.8%N/A7.9 $12.90 11/30/202418,910,000 shares $295.37 million +15.5%N/A7.8 $15.62 Get the Latest News and Ratings for NTLA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/202416,370,000 shares $228.69 million +1.4%N/A7.2 $13.97 10/31/202416,150,000 shares $229.65 million -1.3%N/A8.5 $14.22 10/15/202416,360,000 shares $319.35 million +8.1%N/A11.2 $19.52 9/30/202415,140,000 shares $311.13 million +2.6%N/A10.5 $20.55 9/15/202414,760,000 shares $325.75 million +7.7%N/A9.7 $22.07 8/31/202413,700,000 shares $307.43 million -0.9%N/A9.3 $22.44 8/15/202413,820,000 shares $316.06 million +3.4%N/A8.4 $22.87 7/31/202413,370,000 shares $350.43 million -3.5%N/A8 $26.21 7/15/202413,850,000 shares $360.24 million +4.5%N/A8.4 $26.01 6/30/202413,250,000 shares $296.54 million -3.6%N/A8.4 $22.38 6/15/202413,740,000 shares $345.56 million -6.5%N/A9.4 $25.15 5/31/202414,700,000 shares $314.29 million -3.1%N/A10.4 $21.38 5/15/202415,170,000 shares $397.76 million -1.8%N/A10.7 $26.22 4/30/202415,440,000 shares $330.42 million +5.8%N/A10.5 $21.40 4/15/202414,590,000 shares $334.40 million -1.6%N/A9.5 $22.92 3/31/202414,830,000 shares $407.97 million +9.9%N/A9.6 $27.51 3/15/202413,500,000 shares $382.05 million +7.0%N/A8.6 $28.30 2/29/202412,620,000 shares $405.35 million +8.5%N/A7.6 $32.12 2/15/202411,630,000 shares $331.11 million +6.0%N/A7.5 $28.47 1/31/202410,970,000 shares $261.31 million +5.0%N/A7.1 $23.82 1/15/202410,450,000 shares $289.15 million +2.9%N/A6.8 $27.67 12/31/202310,160,000 shares $309.78 million -3.2%N/A6.8 $30.49 12/15/202310,500,000 shares $323.19 million +6.6%N/A7.2 $30.78 11/30/20239,850,000 shares $291.86 million +4.0%N/A7.6 $29.63 11/15/20239,470,000 shares $251.71 million -1.7%N/A8 $26.58 10/31/20239,630,000 shares $241.23 million +18.6%N/A9.7 $25.05 10/15/20238,120,000 shares $242.22 million -1.1%N/A9.7 $29.83 9/30/20238,210,000 shares $259.60 million +6.2%N/A10.3 $31.62 9/15/20237,730,000 shares $276.89 million -1.4%N/A10 $35.82 8/31/20237,840,000 shares $293.84 million +7.5%N/A9.4 $37.48Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 8/15/20237,290,000 shares $282.92 million +13.9%N/A8.1 $38.81 7/31/20236,400,000 shares $270.91 million +3.1%N/A6.7 $42.33 7/15/20236,210,000 shares $272.99 million +2.5%N/A6.3 $43.96 6/30/20236,060,000 shares $247.13 million +5.4%N/A5.9 $40.78 6/15/20235,750,000 shares $262.03 million +9.7%N/A5.6 $45.57 5/31/20235,240,000 shares $195.24 million -11.8%N/A5 $37.26 5/15/20235,940,000 shares $271.81 million -13.0%N/A5.4 $45.76 4/30/20236,830,000 shares $257.83 million -2.0%N/A6.3 $37.75 4/15/20236,970,000 shares $265.98 million -6.1%N/A6.2 $38.16 3/31/20237,420,000 shares $276.54 million -5.8%N/A6.5 $37.27 3/15/20237,880,000 shares $322.13 million -2.7%N/A6.8 $40.88 2/28/20238,100,000 shares $325.38 million +6.6%N/A6.5 $40.17 2/15/20237,600,000 shares $317.53 million +3.4%N/A6.3 $41.78 1/31/20237,350,000 shares $311.93 million +12.0%N/A6.1 $42.44 1/15/20236,560,000 shares $246.92 million -1.1%N/A5.7 $37.64 12/30/20226,630,000 shares $231.32 million +11.4%N/A6 $34.89 12/15/20225,950,000 shares $217.35 million -1.2%N/A5.4 $36.53 11/30/20226,020,000 shares $309.79 million -9.5%N/A5.2 $51.46 11/15/20226,650,000 shares $351.92 million -5.1%N/A6.7 $52.92 10/31/20227,010,000 shares $369.99 million +6.5%N/A6.7 $52.78 10/15/20226,580,000 shares $344.59 million -4.2%N/A5.8 $52.37 9/30/20226,870,000 shares $384.45 million +2.8%N/A5.9 $55.96 9/15/20226,680,000 shares $458.11 million -2.8%N/A5.2 $68.58 8/31/20226,870,000 shares $412.61 million -1.4%N/A5.5 $60.06 8/15/20226,970,000 shares $476.89 million +3.4%10.2%5.4 $68.42 7/31/20226,740,000 shares $436.48 million -6.7%9.9%5 $64.76 7/15/20227,220,000 shares $456.88 million -3.5%10.6%5.6 $63.28 6/30/20227,480,000 shares $387.16 million +7.0%11.0%5.9 $51.76 6/15/20226,990,000 shares $286.10 million +5.4%10.3%5.9 $40.93 5/31/20226,630,000 shares $305.91 million -4.6%9.8%6.2 $46.14 5/15/20226,950,000 shares $337.77 million +11.4%10.2%5.8 $48.60 4/30/20226,240,000 shares $305.95 million +9.9%9.3%5.5 $49.03 4/15/20225,680,000 shares $340.40 million +1.1%8.5%5 $59.93 3/31/20225,620,000 shares $408.41 million +4.5%8.4%4.8 $72.67 3/15/20225,380,000 shares $313.49 million +1.5%8.0%4.8 $58.27 2/28/20225,300,000 shares $523.91 million +7.3%7.9%4.9 $98.85 2/15/20224,940,000 shares $486.69 million +2.9%7.4%5.2 $98.52 1/31/20224,800,000 shares $453.94 million +10.3%7.2%5.4 $94.57 1/15/20224,350,000 shares $397.46 million +1.9%6.5%5.4 $91.37 12/31/20214,270,000 shares $504.88 million -7.4%6.4%6 $118.24 12/15/20214,610,000 shares $563.80 million +16.1%6.9%6.2 $122.30 11/30/20213,970,000 shares $456.59 million +14.4%5.9%5.4 $115.01 11/15/20213,470,000 shares $463.38 million +4.8%5.2%4.6 $133.54 10/29/20213,310,000 shares $440.16 million -10.3%5.0%4.3 $132.98 10/15/20213,690,000 shares $481.51 million +5.7%5.6%4.1 $130.49 9/30/20213,490,000 shares $468.18 million -0.6%5.3%3.5 $134.15 9/15/20213,510,000 shares $528.04 million +2.3%5.3%1.7 $150.44 8/31/20213,430,000 shares $550.62 million -3.7%5.2%1.6 $160.53 8/13/20213,560,000 shares $553.19 million -2.2%5.4%1.6 $155.39 7/30/20213,640,000 shares $516.33 million +7.1%5.5%1.6 $141.85Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 7/15/20213,400,000 shares $469.54 million -26.6%5.2%1.5 $138.10 6/30/20214,630,000 shares $749.64 million -23.6%7.1%2.1 $161.91 6/15/20216,060,000 shares $537.22 million -7.3%10.1%4.7 $88.65 5/28/20216,540,000 shares $490.11 million -1.5%10.9%5.4 $74.94 5/14/20216,640,000 shares $404.24 million +0.5%N/A4.9 $60.88 4/30/20216,610,000 shares $529.33 million -9.3%N/A4.7 $80.08 4/15/20217,290,000 shares $556.59 million -14.4%N/A4.8 $76.35 3/31/20218,520,000 shares $615.48 million -2.5%N/A5.2 $72.24 3/15/20218,740,000 shares $572.64 million +8.0%N/A5 $65.52 2/26/20218,090,000 shares $464.93 million -5.6%N/A4.5 $57.47 2/12/20218,570,000 shares $590.64 million -9.3%N/A5.1 $68.92 1/29/20219,450,000 shares $604.52 million -2.3%N/A5.7 $63.97 1/15/20219,670,000 shares $805.51 million -4.7%N/A6.2 $83.30 12/31/202010,150,000 shares $574.29 million -8.1%N/A7.1 $56.58 12/15/202011,040,000 shares $575.18 million -5.6%N/A9 $52.10 11/30/202011,700,000 shares $460.75 million -7.1%N/A10.6 $39.38 11/15/202012,590,000 shares $418.37 million -2.3%N/A13 $33.23 10/30/202012,890,000 shares $321.61 million +0.8%N/A14.4 $24.95 10/15/202012,790,000 shares $316.04 million +7.1%N/A14.7 $24.71 9/30/202011,940,000 shares $237.37 million +7.1%N/A14.8 $19.88 9/15/202011,150,000 shares $248.31 million +2.5%N/A13.9 $22.27 8/31/202010,880,000 shares $234.79 million -0.7%N/A13.8 $21.58 8/14/202010,960,000 shares $217.99 million +1.8%N/A11.8 $19.89 7/31/202010,770,000 shares $191.81 million +0.8%N/A10.7 $17.81 7/15/202010,680,000 shares $237.95 million -4.5%26.0%10.8 $22.28 6/30/202011,180,000 shares $228.30 million +11.5%28.0%11.4 $20.42 6/15/202010,030,000 shares $193.98 million -7.2%25.1%10.9 $19.34 5/29/202010,810,000 shares $189.28 million +2.0%24.4%11.5 $17.51 5/15/202010,600,000 shares $187.20 million +2.2%26.5%12.5 $17.66 NTLA Short Interest - Frequently Asked Questions What is Intellia Therapeutics' current short interest? Short interest is the volume of Intellia Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 28,510,000 shares of NTLA short. 28.92% of Intellia Therapeutics' shares are currently sold short. Learn More on Intellia Therapeutics' current short interest. What is a good short interest ratio for Intellia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NTLA shares currently have a short interest ratio of 8.0. Learn More on Intellia Therapeutics's short interest ratio. Which institutional investors are shorting Intellia Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Intellia Therapeutics: FNY Investment Advisers LLC, Wolverine Trading LLC, Group One Trading LLC, D. E. Shaw & Co. Inc., Caption Management LLC, Citadel Advisors LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., PEAK6 LLC, Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Intellia Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 28.92% of Intellia Therapeutics' floating shares are currently sold short. Is Intellia Therapeutics' short interest increasing or decreasing? Intellia Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 28,510,000 shares, an increase of 5.8% from the previous total of 26,940,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Intellia Therapeutics' short interest compare to its competitors? 28.92% of Intellia Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Intellia Therapeutics: SpringWorks Therapeutics, Inc. (11.52%), Akero Therapeutics, Inc. (9.82%), Organon & Co. (6.78%), Merus (9.60%), Crinetics Pharmaceuticals, Inc. (11.05%), Scholar Rock Holding Co. (22.43%), Xenon Pharmaceuticals Inc. (5.51%), Catalyst Pharmaceuticals, Inc. (7.34%), Viking Therapeutics, Inc. (23.97%), Protagonist Therapeutics, Inc. (9.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Intellia Therapeutics stock? Short selling NTLA is an investing strategy that aims to generate trading profit from Intellia Therapeutics as its price is falling. NTLA shares are trading down $0.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Intellia Therapeutics? A short squeeze for Intellia Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NTLA, which in turn drives the price of the stock up even further. How often is Intellia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NTLA, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies SWTX Short Squeeze AKRO Short Squeeze OGN Short Squeeze MRUS Short Squeeze CRNX Short Squeeze SRRK Short Squeeze XENE Short Squeeze CPRX Short Squeeze VKTX Short Squeeze PTGX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NTLA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts